COMMUNIQUÉS West-GlobeNewswire

Globus Medical Reports Fourth Quarter and Full Year 2025 Results
24/02/2026
AUDUBON, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology solutions company, today announced its financial results for the fourth quarter and year ended [...]
Aktis Oncology to Present at Upcoming March Investor Conferences
24/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient [...]
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
24/02/2026
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of [...]
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
24/02/2026
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today [...]
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
24/02/2026
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Cannabix Technologies Closes Non-Brokered Private Placement
24/02/2026
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (the “Company” or “ [...]
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
24/02/2026
DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”) , a global leader in innovations for active healing, today announced that it will report financial results for [...]
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update
24/02/2026
Planning for phase 1/2 clinical trial initiation in Australia utilizing CYWC628 to treat diabetic foot ulcers in the first half of 2026 Improved balance sheet through multiple direct offerings; completed payments of [...]
Teva to Present at the Upcoming Investor Conferences in March
24/02/2026
PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will participate in the [...]
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
24/02/2026
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
24/02/2026
Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating: • Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and [...]
Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives
24/02/2026
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the “Company” or “Werewolf”), an innovative biopharmaceutical company pioneering the development of therapeutics engineered [...]
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
24/02/2026
- Blinded evaluation of safety and tolerability data by the Safety Monitoring Committee from Cohort 1 and advancement to Cohort 2 is expected in 3Q 2026 – - Advancement reflects continued execution of capital-efficient [...]
Dentsply Sirona Appoints James Forbes and Brian McKeon to Board of Directors
24/02/2026
New directors bring decades of financial leadership and board experience to enhance strategic oversight of Return-to-Growth action plan and long-term value creation CHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- [...]
Amwell® to Participate in Upcoming Investor Conference
24/02/2026
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Amwell ® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, today announced that Mark Hirschhorn, CFO and COO, [...]
Rapport Therapeutics to Participate in Upcoming Investor Conferences
24/02/2026
BOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
24/02/2026
LEXINGTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to [...]
Capital Increase in Genmab as a Result of Employee Warrant Exercise
24/02/2026
Company Announcement COPENHAGEN, Denmark; February 24, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 12,313 shares as a consequence of the exercise of employee warrants. The increase is effected [...]
Ceribell Reports Fourth Quarter and Full Year 2025 Financial Results
24/02/2026
SUNNYVALE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]

Pages